All In Biotech

Drug Trial Radar · NCT04511624

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

A Phase I Randomized, Double-Blind, Placebo-Controlled, Single Subcutaneous or Intravenous Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IBI112 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Aug 27, 2020

Primary completion

Jul 22, 2022

Study completion Jul 22, 2022

Sponsor

Sponsor type
Industry
First posted
Aug 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a the first in human study to evaluate the safety, tolerability, PK and PD of single subcutaneous or intravenous dose of IBI112 in healthy subjects

Conditions

  • Healthy Subjects

Interventions

  • IBI112 dose1Drug

    Drug: IBI112 SC dose1 Drug:placebo

  • IBI112 dose2Drug

    Drug: IBI112 SC dose2 Drug:placebo

  • IBI112 dose3Drug

    Drug: IBI112 SC dose3 Drug:placebo

  • IBI112 dose4Drug

    Drug: IBI112 SC dose4 Drug:placebo

  • IBI112 dose5Drug

    Drug: IBI112 IV dose5 Drug:placebo

  • IBI112 dose6Drug

    Drug: IBI112 SC dose6 Drug:placebo

  • IBI112 dose7Drug

    Drug: IBI112 IV dose7 Drug:placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events in healthy volunteers with single ascending doses of IBI112Time frame: Day1 to Day 113 post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.